Role and therapeutic targeting of glutamine metabolism in non-small cell lung cancer (Review)

被引:2
|
作者
Zhou, Lei [1 ]
Zhang, Qi [2 ]
Zhu, Qing [2 ]
Zhan, Yuan [3 ]
Li, Yong [4 ,5 ]
Huang, Xuan [2 ,6 ]
机构
[1] Nanchang Univ, Clin Med Coll 1, Nanchang 330036, Jiangxi, Peoples R China
[2] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330036, Jiangxi, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Pathol, Nanchang 330006, Jiangxi, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Med Ctr Anesthesiol & Pain, Dept Anesthesiol, Nanchang 330006, Jiangxi, Peoples R China
[5] Nanchang Univ, Med Ctr Anesthesiol & Pain, Dept Anesthesiol, Affiliated Hosp 1, 17 Yongwai St, Nanchang 330006, Jiangxi, Peoples R China
[6] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, 1299 Xuefu Rd, Nanchang 330036, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; glutamine metabolism; therapeutic strategies; Warburg effect; metabolism inhibitor; ANTITUMOR-ACTIVITY; GROWTH; INHIBITION; BIOLOGY; GLUTATHIONE; PATHWAYS; EGFR; CLASSIFICATION; PROLIFERATION; SUPPRESSION;
D O I
10.3892/ol.2023.13745
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Warburg effect indicates that cancer cells survive through glycolysis under aerobic conditions; as such, the topic of cancer metabolism has aroused interest. It is requisite to further explore cancer metabolism, as it helps to simultaneously explain the process of carcinogenesis and guide therapy. The flexible metabolism of cancer cells, which is the result of metabolic reprogramming, can meet the basic needs of cells, even in a nutrition-deficient environment. Glutamine is the most abundant non-essential amino acid in the circulation, and along with glucose, comprise the two basic nutrients of cancer cell metabolism. Glutamine is crucial in non-small cell lung cancer (NSCLC) cells and serves an important role in supporting cell growth, activating signal transduction and maintaining redox homeostasis. In this perspective, the present review aims to provide a new therapeutic strategy of NSCLC through inhibiting the metabolism of glutamine. This review not only summarizes the significance of glutamine metabolism in NSCLC cells, but also enumerates traditional glutamine inhibitors along with new targets. It also puts forward the concept of combination therapy and patient stratification with the aim of comprehensively showing the effect and prospect of targeted glutamine metabolism in NSCLC therapy. This review was completed by searching for keywords including 'glutamine', 'NSCLC' and 'therapy' on PubMed, and screening out articles.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] The Role of Autophagia in Non-Small Cell Lung Cancer
    Sever, Ozlem N.
    Demir, Gokhan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2017, 27 (03): : 185 - 192
  • [42] Is there a role for cetuximab in non-small cell lung cancer?
    Morgensztern, Daniel
    Govindan, Ramaswamy
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4602S - 4605S
  • [43] Role of pemetrexed in non-small cell lung cancer
    Longo-Sorbello, Giuseppe S. A.
    Chen, Bobin
    Budak-Alpdogan, Tulin
    Bertino, Joseph R.
    CANCER INVESTIGATION, 2007, 25 (01) : 59 - 66
  • [44] Aumolertinib: A Review in Non-Small Cell Lung Cancer
    Shirley, Matt
    Keam, Susan J.
    DRUGS, 2022, 82 (05) : 577 - 584
  • [45] Docetaxel in non-small cell lung cancer: a review
    Davies, AM
    Lara, PN
    Mack, PC
    Gandara, DR
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 553 - 565
  • [46] Aumolertinib: A Review in Non-Small Cell Lung Cancer
    Matt Shirley
    Susan J. Keam
    Drugs, 2022, 82 : 577 - 584
  • [47] Erlotinib in non-small cell lung cancer: a review
    Blackhall, FH
    Rehman, S
    Thatcher, N
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 995 - 1002
  • [48] Bronchoscopy Diagnostic and Therapeutic for Non-Small Cell Lung Cancer
    Bauer, Thomas L.
    Berkheim, David B.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 25 (03) : 481 - +
  • [49] Therapeutic options for oligoprogressive non-small cell lung cancer
    Gustin, P.
    Botticella, A.
    Tselikas, L.
    Mercier, O.
    Le Pechoux, C.
    Levy, A.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (04) : 519 - 526
  • [50] Molecular therapeutic targets in non-small cell lung cancer
    Sankar, Kamya
    Gadgeel, Shirish M.
    Qin, Angel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (08) : 647 - 661